News

ISOThrive Awarded Composition of Matter and Production Method Patent for its First “Farmaceutical™” to Support Animal Health

ISOThrive Inc., a microbiome therapeutics company announced that the U.S. Patent and Trademark Office has issued a Composition of Matter and Production Method patent for its first Farmaceutical™ Maltosyl-Isomaltooligosaccharides (MIMO™), a prebiotic for use as an animal feed additive and pet food supplement. USDA and University of GA studies showed MIMO as highly effective at protecting chickens against antibiotic resistant Salmonella while improving feed efficiency.

ISOThrive opens up a whole new market opportunity to offer higher quality meats that are free of pathogens and also leaner. At the same time, increased food safety is better for workers, less costly for producers and better for the environment. Plus, there are emerging opportunities in pet health with supplements that support better digestion with less reliance on medications.

The widespread use of antibiotics in cattle, swine and chickens can lead to the creation of antibiotic resistant bacterial species.  The same antibiotics used in animal feed are also used to treat disease in humans. With the rise of antibiotic resistant bacteria, eliminating their use in livestock has become a necessity. Prebiotics, while offering a viable alternative to antibiotics, can be expensive to manufacture. This patent covers an economical and efficient method for making (MIMO) that can be used as an additive for animal feed at significantly lower cost.

“Today’s conscious consumer wants a healthier food supply, a better environment for the people that produce the food and has the least amount of environmental impact,” said Jack Oswald, ISOThrive’s CEO, CTO and Co-Founder. “This new patent allows us to open a new market opportunity while simultaneously positively impacting food safety and security at a cost that makes sense for producers.”

Researchers at USDA and University of Georgia found that MIMO added to chicken feed reduced antibiotic resistant Salmonella by 99% while increasing Bifidobacteria.  Feed efficiency was increased by 9-10%.

 

Recent News

04/02/2025

VCU startup wins $800k grant to propel its infection-fighting surgical gel

With an innovation that could advance brain and spinal surgeries, a Virginia Commonwealth University startup has received an $800,000 state grant to support development of its infection-fighting gel. Pascal Medical Corp. is one of four grant recipients to receive awards from Virginia Catalyst, a nonprofit created by the General Assembly and funded by the state’s general

04/02/2025

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application

04/02/2025

Charlottesville Angel Network Celebrates 10 Years, Surpasses $20 Million in Investments

The Charlottesville Angel Network (CAN), a group of accredited investors dedicated to supporting early-stage ventures, proudly marks its 10th anniversary this month. Since its inception, CAN angel investor members have invested more than $20 million in nearly 80 startups, fostering innovation both locally and beyond. Reflecting on a decade of achievements, CAN has realized returns